Stock events for Rocket Pharmaceuticals, Inc. (RCKT)
Over the past six months, Rocket Pharmaceuticals' stock has increased by 36.53%, but decreased by 51.54% over the past year, with a 52-week range between $2.19 and $9.81. Key events include the FDA acceptance of the BLA resubmission for Kresladi™ (LAD-I), Q4 and full-year 2025 financial results with an EPS of ($0.38) beating estimates, insider trading activity, analyst ratings averaging "Hold" with a target price of $14.36, and a clinical hold on RP-A501 (Danon disease) that was subsequently lifted.
Demand Seasonality affecting Rocket Pharmaceuticals, Inc.’s stock price
As a clinical-stage biotechnology company without commercial products, Rocket Pharmaceuticals, Inc. does not have demand seasonality in the traditional sense. Stock price seasonality analysis indicates June has historically shown the highest probability of positive returns, while January has the lowest, but this pertains to stock market trends, not product demand.
Overview of Rocket Pharmaceuticals, Inc.’s business
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare pediatric diseases, utilizing lentiviral vector (LVV) and adeno-associated viral vector (AAV) platforms. Its product candidates include LVV-based therapies for Fanconi Anemia (RP-L102), Leukocyte Adhesion Deficiency-I (RP-L201) with a BLA resubmission accepted by the FDA, and Pyruvate Kinase Deficiency (RP-L301). AAV-based therapies target Danon disease (RP-A501), Plakophilin-2 Arrhythmogenic Cardiomyopathy (RP-A601), and BAG3 Dilated Cardiomyopathy.
RCKT’s Geographic footprint
Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey, with R&D and Corporate Headquarters in Cranbury, NJ, and an additional office in New York, NY.
RCKT Corporate Image Assessment
Rocket Pharmaceuticals' brand reputation has been influenced by clinical trial progress and inherent biotechnology sector risks. The acceptance of the BLA resubmission for Kresladi™ is a positive development, while the clinical hold on the RP-A501 trial for Danon disease raised concerns despite being later lifted. The company's management has been noted for its adaptability and transparency in handling these setbacks.
Ownership
Rocket Pharmaceuticals, Inc. has significant institutional ownership, ranging from 92.34% to 98.4%, while insider ownership is approximately 3.07% to 24.8%. Major institutional owners include RTW Investments, LP, The Vanguard Group, Inc., and BlackRock, Inc., among others.
